alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Fourth Court of Appeals

San Antonio, Texas

August 1, 2019

No. 04-19-00374-CV

Adam REPOSA,

Appellant

v.

Keith HENNEKE and David Escamilla,

Appellees

From the 425th Judicial District Court, Williamson County, Texas

Trial Court No. 18-1071-C425

Honorable David Peeples, Judge Presiding

O R D E R

On July 2, 2019, we issued an order in which we informed appellant that the trial court 

clerk filed a notification of late record stating that appellant failed to pay or make arrangements 

to pay the fee for preparing the clerk’s record and that appellant is not entitled to preparation of 

the clerk’s record without paying the fee. In our July 2, 2019 order, we directed appellant to 

provide written proof to this court that either (1) the clerk’s fee has been paid or arrangements 

have been made to pay the clerk’s fee; or (2) appellant is entitled to appeal without paying the 

clerk’s fee. Appellant has not responded to our order.

Additionally, on July 25, 2019, the court reporter filed a notification of late record stating 

that appellant failed to request a reporter’s record and also failed to pay or make arrangements to 

pay the fee for preparing the reporter’s record and that appellant is not entitled to preparation of 

the reporter’s record without paying the fee.

It is therefore ORDERED that appellant provide written proof to this court on or before 

August 6, 2019 that either (1) the clerk’s fee has been paid or arrangements have been made to 

pay the clerk’s fee; or (2) appellant is entitled to appeal without paying the clerk’s fee. If 

appellant fails to respond within the time provided with regard to the portion of this order 

regarding the clerk’s order, this appeal will be dismissed for want of prosecution. See TEX. R.

APP. P. 37.3(b); see also TEX. R. APP. P. 42.3(c) (allowing dismissal of appeal if appellant fails to 

comply with an order of this court). 
We additionally ORDER appellant to file written proof to this court on or before August 

12, 2019 that he has filed a designation of record with the court reporter. See TEX. R. APP. P.

34.6(b)(c). We further ORDER appellant to provide written proof to this court within ten days 

of the date of this order that either (1) the reporter’s fee has been paid or arrangements have been 

made to pay the reporter’s fee; or (2) appellant is entitled to appeal without paying the reporter’s 

fee. If appellant fails to respond to the portion of this record regarding the reporter’s record 

within the time provided, the court will only consider those issues or points raised in appellant’s 

brief that do not require a reporter’s record for a decision. See TEX. R. APP. P. 37.3(c).

_________________________________

Irene Rios, Justice

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the seal of the said 

court on this 1st day of August, 2019.

___________________________________

KEITH E. HOTTLE,

Clerk of Court
NOTE: This disposition is nonprecedential.

United States Court of Appeals 

for the Federal Circuit ______________________ 

LUITPOLD PHARMACEUTICALS, INC.,

Appellant

v.

PHARMACOSMOS A/S,

Cross-Appellant

______________________ 

2017-1715, 2017-1725

______________________ 

Appeals from the United States Patent and Trademark Office, Patent Trial and Appeal Board in Nos. 

IPR2015-01490, IPR2015-01493.

______________________ 

JUDGMENT

______________________ 

GEORGE ELLSWORTH QUILLIN, Foley & Lardner LLP, 

Washington, DC, argued for appellant. Also represented 

by MICHAEL D. KAMINSKI, BRADLEY D. ROUSH, NATASHA 

IYER. 

 PAUL RAGUSA, Baker Botts, LLP, New York, NY, 

argued for cross-appellant. Also represented by LISA 

KOLE, STEVEN LENDARIS, JENNIFER COZEOLINO TEMPESTA. 

______________________ 
 

THIS CAUSE having been heard and considered, it is

ORDERED and ADJUDGED: 

 PER CURIAM (PROST, Chief Judge, WALLACH and 

TARANTO, Circuit Judges).

AFFIRMED. See Fed. Cir. R. 36.

 ENTERED BY ORDER OF THE COURT

 April 12, 2018 /s/ Peter R. Marksteiner 

 Date Peter R. Marksteiner

 Clerk of Court
#### Charles Michael STOKES, Plaintiff—Appellant, v. Andrew MOORMAN, sued in his individual and official capacities, Defendant—Appellee.

No. 10-7411.

United States Court of Appeals, Fourth Circuit.

Submitted: Dec. 21, 2010.

Decided: Jan. 4, 2011.

Charles Michael Stokes, Appellant Pro Se.

Before NIEMEYER and KEENAN, Circuit Judges, and HAMILTON, Senior Circuit Judge.

Affirmed by unpublished PER CURIAM opinion.

Unpublished opinions are not binding precedent in this circuit.

PER CURIAM:

Charles M. Stokes appeals the district court’s order accepting the recommendation of the magistrate judge and denying relief on his 42 U.S.C. § 1983 (2006) complaint. We have reviewed the record and find no reversible error. Accordingly, we affirm for the reasons stated by the district court. *Stokes v. Moorman,*No. 9:10-cv-01711-CMC, 2010 WL 3834470 (D.S.C. Sept. 27, 2010). We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

*AFFIRMED.*
Unassociated Document


    AMENDMENT
      NO. 1

    


    


    This
      Amendment Number 1 to Research and Development Agreement
      (this
“Amendment No. 1”) is made and entered into effective as of this 14th
      day of
      August, 2006 by and among NuWay Medical, Inc., BioLargo Life Technologies,
      Inc,
      IOWC Technologies, Inc. and Kenneth Reay Code. Capitalized terms used herein
      without definitions shall have the same meanings as defined in the Research
      and
      Development Agreement by and among the parties hereto dated August 11, 2006
      (the
“R&D Agreement”)

     

    1.
      The
      Parties agree that NuWay and BLTI will cooperate with IOWC in setting the
      timetable for the creation or establishment of facilities appropriate for IOWC
      and Code to conduct the Work, as defined in the R&D Agreement and,
      notwithstanding the provisions of Section 2(a) of the R&D Agreement, no fees
      shall be payable to IOWC pursuant to that Section until such time as facilities
      are established to mutual satisfaction of the Parties.

     

    2.
      Except
      as modified by this Amendment No. 1, the R&D Agreement is, and remains, in
      full force and effect in accordance with its terms.

     

    In
      Witness Whereof, the Parties have executed this Amendment No. 1 effective this
      14th
      day of
      August, 2006.

     

     

    
      	IOWC
              TECHNOLOGIES,
              INC.	 	 
	 	 
	 
 	 
 	 
 
	
              By:  /s/ Kenneth R.
                Code                       
                

                       President

            	       
               	
              /s/
                Kenneth R.
                Code                             
                

              KENNETH REAY CODE

            
	 	 	 
	NUWAY MEDICAL,
              INC.	BIOLARGO LIFE 
	 	TECHNOLOGIES,
              INC.
	 	 
	 	 
	
              By: /s/ Dennis
                Calvert                             

            	By:
              /s/ Dennis
              Calvert                         
	
                  
                President

            	
                 
                President
EXHIBIT 32.2

SECTION 1350 CERTIFICATION

In connection with the report of Inuvo, Inc. (the "Company") on Form 10-Q for the period ended September 30, 2009, as filed with the Securities and Exchange Commission (the "Report"), I, Gail L. Babitt, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

|                        |                                                                                    
|----------------------- | -----------------------------------------------------------------------------------
|Date: November 23, 2009 | /s/ Gail L. Babitt                                                                 
|                        | Gail L. Babitt
Chief Financial Officer, 
Principal Financial and Accounting Officer



A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
Exhibit 31.1  CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002  I, Mark L. Meriwether, certify that:  1.   I have reviewed this Quarterly Report (the Report) on Form 10-QSB of the small business issuer;  2.   Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report;  3.   Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this Report;  4.   The small business issuers other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and have:  a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this Report is being prepared;  b) evaluated the effectiveness of the small business issuers disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation; and  c) disclosed in this Report any change in the small business issuers internal control over financial reporting that occurred during the small business issuers most recent fiscal quarter (the small business issuers fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuers internal control over financial reporting; and  5.   The small business issuers other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuers auditors and the audit committee of the small business issuers board of directors (or persons performing the equivalent functions);  a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuers ability to record, process, summarize and report financial information; and  b) any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuers internal control over financial reporting.  Date:May 15, 2007By:/s/Mark L. MeriwetherMark L. Meriwether, President and Director
<TABLE> <S> <C>


<ARTICLE>                     5
       
<S>                           <C>
<PERIOD-TYPE>                 3-MOS
<FISCAL-YEAR-END>             JUN-30-1997
<PERIOD-END>                  MAR-31-1997
<CASH>                        5,750
<SECURITIES>                  0
<RECEIVABLES>                 0
<ALLOWANCES>                  0
<INVENTORY>                   0
<CURRENT-ASSETS>              0
<PP&E>                        89,090
<DEPRECIATION>                (48,268)
<TOTAL-ASSETS>                83,607
<CURRENT-LIABILITIES>         3,683,387
<BONDS>                       0
<PREFERRED-MANDATORY>         0
<PREFERRED>                   501,700
<COMMON>                      300,000
<OTHER-SE>                    (3,998,080)
<TOTAL-LIABILITY-AND-EQUITY>  83,607
<SALES>                       0
<TOTAL-REVENUES>              0
<CGS>                         0
<TOTAL-COSTS>                 383,267
<OTHER-EXPENSES>              0
<LOSS-PROVISION>              0
<INTEREST-EXPENSE>            0
<INCOME-PRETAX>               (383,267)
<INCOME-TAX>                  0
<INCOME-CONTINUING>           0
<DISCONTINUED>                0
<EXTRAORDINARY>               0
<CHANGES>                     0
<NET-INCOME>                  (383,267)
<EPS-PRIMARY>                 (.01)
<EPS-DILUTED>                 0
        


</TABLE>
Exhibit 32.2
                    CERTIFICATION OF CHIEF FINANCIAL OFFICER
                             PURSUANT TO SECTION 906
                        OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Symbollon Pharmaceuticals, Inc. (the
Company) on Form 10-KSB for the year ending December 31, 2003 as filed with the
Securities and Exchange Commission on the date hereof (the Report), I, Paul C.
Desjourdy, Chief Financial Officer of the Company, certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that:

1.       The Report fully complies with the  requirements of Section 13(a) or
         15(d) of the Securities  Exchange Act of 1934; and

2.       The information contained in the Report fairly presents, in all
         material respects, the financial condition and results of operations of
         the Company.

Date: March 30, 2004          /s/ Paul C. Desjourdy
                              -----------------------------------
                              Paul C. Desjourdy
                              Chief Financial Officer
NOT FOR PUBLICATION

UNITED STATES COURT OF APPEALS

FOR THE NINTH CIRCUIT

JULIO HERNANDEZ OLIVOS, AKA Julio

Hernandez,

Petitioner,

v.

MERRICK B. GARLAND, Attorney General,

Respondent. No. 19

- 72380

Agency No. A215

- 855

- 171

MEMORANDUM *

On Petition for Review of an Order of the

Board of Immigration Appeals

Submitted August 10, 2022 * *

Anchorage, Alaska

Before: S.R. THOMAS, McKEOWN, and CLIFTON, Circuit Judges.

Julio Hernandez Olivos, a native of Mexico, seeks review of a decision of the

Board of Immigration Appeals (“BIA”) affirming the Immigration Judge’s denial of

a continuance and denying petitioner’s motion to remand. We review both decision s

* This disposition is not appropriate for publication and is not precedent

except as provided by Ninth Circuit Rule 36

- 3.

** The panel unanimously concludes this case is suitable for decision

without oral argument. See Fed. R. App. P. 34(a)(2). 

# FILED

AUG 12 2022

MOLLY C. DWYER, CLERK

U.S. COURT OF APPEALS2

for abuse of discretion. Orozco

- Lopez v. Garland

, 11 F.4th 764, 774 (9th Cir. 2021)

(continuance) ; Taggar v. Holder , 736 F.3d 886, 889 (9th Cir. 2013) (remand).

The BIA did not abuse its discretion by affirming the IJ’s denial of a continuance

. Hernandez Olivos did not meet his burden of showing that his visa petition

was prima facie approvable under the “bona fide marriage” exemption, 8 C.F.R.

§§ 204.2(a)(l)(iii)

.

The BIA did not abuse its discretion by denying the motion to remand based

on its determination that the new evidence would not constitute exceptional and extremely unusual hardship. See Aguilar

- Osorio v. Garland , 991 F.3d 997, 999

(9th Cir. 2021) ( “ This court does not have jurisdiction to review the merits of the

BIA ’ s discretiona ry decision to deny cancellation of removal based on hardship. ”).

PETITION FOR REVIEW DENIED.
Exhibit 11.1

                              SYMBOLLON CORPORATION

                 STATEMENT RE COMPUTATION OF PER SHARE EARNINGS

                                                 The Years Ended December 31,
                                           -------------------------------------
                                                1997                  1996
                                           --------------        --------------


 Net Income (Loss) .....................   $     511,464         $    (905,415)

 Preferred Stock Dividend...............                               (15,233)
                                           --------------        --------------
 Net Income (Loss) on Per Share Basis...   $     511,464         $    (920,648)
                                           ==============        ==============


 Net Income (Loss) per common share:
     Weighted average common shares
     outstanding........................       2,868,783             2,434,019


     Shares subject to restriction......        (700,000)             (700,000)
                                           --------------        --------------
                                               2,168,783             1,734,019
                                           ==============        ==============


 Net Income (Loss) per common share.....   $        0.24         $       (0.52)
                                           ==============        ==============



Net Income (Loss) per common share - assuming dilution:

     Weighted average common shares
     outstanding........................       2,868,783

     Weighted average dilutive potential
     common shares outstanding..........         191,550

     Shares subject to restriction......        (700,000)
                                           --------------
                                               2,360,333
                                           ==============


 Net Income per common share
     - assuming dilution (1)............   $        0.22
                                           ==============

(1)  For the year ended December 31, 1996, there is no difference between basic
     and duluted loss per share.
Exhibit 15.2



|     |  |                                                                                                  |  |                                                             
|---- |  | ------------------------------------------------------------------------------------------------ |  | ------------------------------------------------------------
|LOGO |  | KPMG Auditores Consultores Ltda. Av.
Isidora Goyenechea 3520, Piso 2 Las Condes, Santiago, Chile |  | Teléfono +56 (2) 2798 1000
Fax +56 (2) 2798 1001 www.kpmg.cl

Consent of Independent Registered Public Accounting Firm

The Board of Directors and Shareholders of

Empresa Nacional de
Electricidad S.A. (Endesa-Chile):

We consent to the incorporation by reference in the registration statement on Form F-4 of Enersis Américas S.A.
(No. 333-211405) of our report dated April 29, 2016, with respect to the consolidated statements of financial position of Endesa-Chile and its subsidiaries as of December 31, 2015 and 2014, and the related consolidated statements of
comprehensive income, changes in equity, and cash flows for each of the years in the three-year period ended December 31, 2015, and the effectiveness of internal control over financial reporting as of December 31, 2015, appearing in the Annual
Report on Form 20-F of Enersis Américas S.A. for the year ended December 31, 2015.



|                                
|--------------------------------
|/s/ KPMG                        
|KPMG Auditores Consultores Ltda.
|Santiago, Chile                 
|September 6, 2016               

KPMG Auditores Consultores Ltda, a Chilean limited liability partnership and a member firm of the KPMG network of independent
member firms affiliated with KPMG International Cooperative (KPMG International), a Swiss entity. All rights reserved.
INDEPENDENT AUDITOR'S REPORT


The Board of Directors
Fidelity Bancorp, Inc.
Chicago, Illinois:



We have audited the accompanying consolidated statements of financial condition
of Fidelity Bancorp, Inc. (the Company) and subsidiary as of September 30,
1999, and the related consolidated statements of earnings, changes in
stockholders' equity, and cash flows for each of the years in the two-year
period ended September 30, 1999.  These consolidated financial statements are
the responsibility of the Company's management.  Our responsibility is to
express an opinion on these consolidated financial statements based on our
audits.

We conducted our audits in accordance with generally accepted auditing
standards.  Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of
material misstatement.  An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements.  An audit
also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial
statement presentation.  We believe that our audits provide a reasonable basis
for our opinion.

In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the financial position of Fidelity Bancorp,
Inc. and subsidiary as of September 30, 1999, and the results of their
operations and their cash flows for each of the years in the two-year period
ended September 30, 1999, in conformity with generally accepted accounting
principles.




                                                          KPMG LLP


Chicago, Illinois
October 22, 1999
2023 ਦੀਆਂ ਕਾਊਂਟੀ ਕਮੇਟੀ 

ਚੋਣਾਂ

15 ਜੂਨ, 2023

ਨਾਮਜ਼ਦਗੀ ਦੀ ਮਿਆਦ 

ਦੀ ਸ਼ੁਰੂਆਤ। fsa.usda.

gov/elections ਤੇ 

ਫਾਰਮ ਉਪਲਬਧ ਹਨ।

1 ਅਗਸਤ, 2023

ਸਥਾਨਕ FSA ਕਾਉਂਟੀ 

ਦਫਤਰ ਵਿਖੇ ਨਾਮਜ਼ਦਗੀ 

ਫਾਰਮ ਭਰਨ ਦਾ ਆਖਰੀ 

ਦਿਨ।

6 ਨਵੰਬਰ, 2023

ਬੈਲਟ ਯੋਗ ਵੋਟਰਾਂ 

ਨੂੰ ਡਾਕ ਰਾਹੀਂ ਭੇਜੇ 

ਜਾਂਦੇ ਹਨ।

4 ਦਸੰਬਰ, 2023

ਸਥਾਨਕ FSA ਕਾਉਂਟੀ 

ਦਫਤਰ ਨੂੰ ਵੋਟ ਕੀਤੇ 

ਬੈਲਟ ਵਾਪਸ ਕਰਨ ਦਾ 

ਆਖਰੀ ਦਿਨ।

1 ਜਨਵਰੀ, 2024

ਨਵੇਂ ਚੁਣੇ ਗਏ ਕਾਉਂਟੀ 

ਕਮੇਟੀ ਮੈਂਬਰ ਅਹੁਦਾ 

ਸੰਭਾਲਣਗੇ।

ਕੜੀ ਬਣੋ

ਤੁਹਾਡੇ ਖੇਤੀਬਾੜੀ ਭਾਈਚਾਰੇ ਅਤੇ USDA ਵਿਚਕਾਰ

ਜੂਨ 2023 USDA ਇੱਕ ਬਰਾਬਰ ਮੌਕੇ ਵਾਲਾ ਪ੍ਰਦਾਨਕ, ਰੁਜ਼ਗਾਰਦਾਤਾ ਅਤੇ ਰਿਣਦਾਤਾ ਹੈ

ਖੇਤੀ ਸੇਵਾ ਏਜੰਸੀ

U.S. ਖੇਤੀਬਾੜੀ ਵਿਭਾਗ
<PAGE>

                 OPINION RESEARCH CORPORATION AND SUBSIDIARIES
                  Exhibit (21) Subsidiaries of the Registrant



Name of Incorporation                 State or Other          Date of
   or Organization                     Jurisdiction         Incorporation
---------------------                 --------------        --------------

Macro International Inc.               Delaware             March 17, 1972

ORC, Inc.                              Delaware             December 16, 1991

European Information Centre Limited    United Kingdom       December 20, 1991

ORC Holdings, Ltd.                     United Kingdom       July 17, 1996

ORC Korea, Ltd.                        Korea                November 30, 1996

ORC International Holdings, Inc.       Cayman Islands       March 18, 1997

ORC TeleService Corp.                  Delaware             March 26, 1997

Opinion Research Corporation,
    S.A. de C.V.                       Mexico, D.F.         July 10, 1997

ORC ProTel, Inc.                       Delaware             November 20, 1997

O.R.C. International, Ltd.             United Kingdom       December 15, 1997